[Analysis of clinicopathological characteristics of papillary thyroid carcinoma and BRAF V600E gene mutation]

Y Zhao; H Y Wang; C B Wang; M Niu; Y Y Wang; X F Li

doi:10.13201/j.issn.1001-1781.2018.19.007

[Analysis of clinicopathological characteristics of papillary thyroid carcinoma and BRAF V600E gene mutation]

Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 2018 Oct 5;32(19):1472-1476. doi: 10.13201/j.issn.1001-1781.2018.19.007.

[Article in Chinese]

Authors

Y Zhao¹, H Y Wang¹, C B Wang¹, M Niu², Y Y Wang¹, X F Li¹

Affiliations

¹ Department of Pathology, the First Affiliated Hospital of Xi'an Jiaotong University, Xi'an，710061, China.
² Department of Pathology, the Fourth Hospital of Xi'an.

PMID: 30550190
DOI: 10.13201/j.issn.1001-1781.2018.19.007

Abstract

Objective: To study the correlation between the BRAF V600E mutation and the clinicopathological features of papillary thyroid carcinoma(PTC), and to explore the application value of BRAF V600E mutation in PTC. Method: The BRAF V600E gene mutation was detected in 108 PTC cases and 30 control cases by qPCR. The results were statistically analyzed by using SPSS 21.0 software. Result: The BRAF V600E mutation was absent in the control group. The BRAF V600E mutation rate was 72.20% in 108 PTC cases. Compared with patients with wild type,the mean age of patients with the mutant BRAF V600E was significantly older(P<0.05). BRAF V600E mutations were associated with PTC tissue subtypes and central area lymph node metastasis(P<0.05). BRAF V600E mutations were not correlated with tumor diameter, patient gender, multifocality, tumor site, concomitant disease, lymph node metastasis in side region of neck, capsule invasion, and TNM staging(P>0.05). Conclusion: The value of BRAF V600E mutation in the prognosis of PTC remains to be studied. BRAF V600E mutation is of value for pathological diagnosis of PTC.

Keywords: BRAF V600E gene; pathological examination; thyroid neoplasms.

Publication types

English Abstract